News & Media
Media
FEATURED
Learn more about our ACCUM technology
Making a Global Impact
News Releases
Defence Therapeutics Invites Shareholders To Its December 10, 2026, Annual General Meeting And 2027 Strategic Update
Montreal, QC, Canada, November 16, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”) (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to invite shareholders to its upcoming...
2026 Audited Financial Statement and MD&A
2026 Audited FS 2026 MD&AAbout Defence: Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum® precision drug delivery platform, Defence is working to enhance the potency of...
Defence Therapeutics Announces Convertible Debenture Interest Payment
Montreal, QC, Canada, October 23rd, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in The Field Highlighting the Potential of its Accum Platform
Montreal, QC, Canada, October 19th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Montreal, QC, Canada, October 1st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, QC, Canada, September 29, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, QC, Canada, September 28, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”) (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, QC, Canada, September 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Provides Updates on Sharing Agreement
Montreal, QC, Canada, September 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to provide an update on its sharing...
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Montreal, QC, Canada, August 31st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Strengthens Radiopharmaceutical Leadership With Appointment Of Dr. Ryan Simms As Chief Operating Officer And Head Of Radiopharmaceutical Programs
Montreal, QC, Canada, August 17, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...
Defence Therapeutics Appoints Dr. Amie Phinney As President And Chief Executive Officer
Montreal, QC, Canada, August 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum®...







